FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953618443> ?p ?o ?g. }

• W2953618443 endingPage "1162" @default.
• W2953618443 startingPage "1162" @default.
• W2953618443 abstract "Isotretinoin is a highly effective medication for severe acne. Although no causal link between isotretinoin and psychiatric adverse effects has been established, widespread media reporting of depression and suicidality with use of isotretinoin have raised concerns in both patients and clinicians and generated numerous cases of costly litigation.To evaluate reports of psychiatric adverse events associated with isotretinoin use submitted to the US Food and Drug Administration from January 1, 1997, through December 31, 2017.This retrospective study evaluated reports of psychiatric adverse events with isotretinoin as the primary suspect drug in the US Food and Drug Administration's Adverse Event Reporting System from 1997 through 2017. Publicly available data on number of patients enrolled in the iPLEDGE program were used to calculate rates of completed suicide per 100 000 patients enrolled in iPLEDGE in 2009 and 2010. All data were analyzed between July 1, 2018, and January 31, 2019.The main outcomes were frequency and type of psychiatric adverse events in patients taking isotretinoin. Secondary analyses were stratification by age and sex and evaluation of completed suicide rates.Between 1997 and 2017, 17 829 psychiatric adverse events with isotretinoin use were reported to the US Food and Drug Administration, with depressive disorders, emotional lability, and anxiety disorders reported most frequently. Of these events, 8936 (50.1%) were reported among men and 8362 (46.9%) among women; the sex of the individual was not reported for 531 events (3.0%). Of the 13 553 reports that included patient age, the mean (SD) age was 22.1 (8.6) years. More than half (52.5%) of all events occurred in 10- to 19-year-old individuals. Whereas depression and anxiety were reported equally between sexes, eating disorders were more common in females (58 of 85 [68.2%]), while attention-deficit/hyperactivity disorder (55 of 83 events [66.3%]) and completed suicides (290 of 368 [78.8%]) were more common in males. The rates of completed suicide were 8.4 and 5.6 suicides per 100 000 patients enrolled in iPLEDGE in 2009 and 2010, respectively.Although depressive disorders and suicidality were frequently reported with isotretinoin use, these reports must be considered in the context of elevated rates of depression and suicide among patients with acne at large. These data suggest that the rate of completed suicide in patients taking isotretinoin may be lower than that of the general US population. Many psychiatric adverse events unrelated to depression and suicidality were also reported, but it is unclear if they were a result of isotretinoin therapy. Although no causal link between isotretinoin and psychiatric risk has been established, patients taking the drug appear vulnerable to psychiatric concerns. Mandated monthly iPLEDGE visits may provide an opportunity to screen patients for psychiatric conditions and improve outcomes." @default.
• W2953618443 created "2019-07-12" @default.
• W2953618443 creator A5005697587 @default.
• W2953618443 creator A5016027668 @default.
• W2953618443 creator A5037026685 @default.
• W2953618443 creator A5053193999 @default.
• W2953618443 creator A5083722360 @default.
• W2953618443 date "2019-10-01" @default.
• W2953618443 modified "2023-10-15" @default.
• W2953618443 title "Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017" @default.
• W2953618443 cites W1965851263 @default.
• W2953618443 cites W1983185705 @default.
• W2953618443 cites W2005922571 @default.
• W2953618443 cites W2009890917 @default.
• W2953618443 cites W2025600313 @default.
• W2953618443 cites W2036080233 @default.
• W2953618443 cites W2057948658 @default.
• W2953618443 cites W2077366569 @default.
• W2953618443 cites W2128007007 @default.
• W2953618443 cites W2147797128 @default.
• W2953618443 cites W2150501731 @default.
• W2953618443 cites W2426571646 @default.
• W2953618443 cites W2593517040 @default.
• W2953618443 cites W2596173704 @default.
• W2953618443 cites W2778437737 @default.
• W2953618443 cites W2792723400 @default.
• W2953618443 cites W2794727259 @default.
• W2953618443 cites W4249508602 @default.
• W2953618443 doi "https://doi.org/10.1001/jamadermatol.2019.1416" @default.
• W2953618443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6613309" @default.
• W2953618443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31268488" @default.
• W2953618443 hasPublicationYear "2019" @default.
• W2953618443 type Work @default.
• W2953618443 sameAs 2953618443 @default.
• W2953618443 citedByCount "42" @default.
• W2953618443 countsByYear W29536184432019 @default.
• W2953618443 countsByYear W29536184432020 @default.
• W2953618443 countsByYear W29536184432021 @default.
• W2953618443 countsByYear W29536184432022 @default.
• W2953618443 countsByYear W29536184432023 @default.
• W2953618443 crossrefType "journal-article" @default.
• W2953618443 hasAuthorship W2953618443A5005697587 @default.
• W2953618443 hasAuthorship W2953618443A5016027668 @default.
• W2953618443 hasAuthorship W2953618443A5037026685 @default.
• W2953618443 hasAuthorship W2953618443A5053193999 @default.
• W2953618443 hasAuthorship W2953618443A5083722360 @default.
• W2953618443 hasBestOaLocation W29536184431 @default.
• W2953618443 hasConcept C118552586 @default.
• W2953618443 hasConcept C126322002 @default.
• W2953618443 hasConcept C139719470 @default.
• W2953618443 hasConcept C16005928 @default.
• W2953618443 hasConcept C162324750 @default.
• W2953618443 hasConcept C187212893 @default.
• W2953618443 hasConcept C197934379 @default.
• W2953618443 hasConcept C2776285725 @default.
• W2953618443 hasConcept C2776867660 @default.
• W2953618443 hasConcept C2777105317 @default.
• W2953618443 hasConcept C2777673923 @default.
• W2953618443 hasConcept C3018890749 @default.
• W2953618443 hasConcept C545542383 @default.
• W2953618443 hasConcept C71924100 @default.
• W2953618443 hasConceptScore W2953618443C118552586 @default.
• W2953618443 hasConceptScore W2953618443C126322002 @default.
• W2953618443 hasConceptScore W2953618443C139719470 @default.
• W2953618443 hasConceptScore W2953618443C16005928 @default.
• W2953618443 hasConceptScore W2953618443C162324750 @default.
• W2953618443 hasConceptScore W2953618443C187212893 @default.
• W2953618443 hasConceptScore W2953618443C197934379 @default.
• W2953618443 hasConceptScore W2953618443C2776285725 @default.
• W2953618443 hasConceptScore W2953618443C2776867660 @default.
• W2953618443 hasConceptScore W2953618443C2777105317 @default.
• W2953618443 hasConceptScore W2953618443C2777673923 @default.
• W2953618443 hasConceptScore W2953618443C3018890749 @default.
• W2953618443 hasConceptScore W2953618443C545542383 @default.
• W2953618443 hasConceptScore W2953618443C71924100 @default.
• W2953618443 hasIssue "10" @default.
• W2953618443 hasLocation W29536184431 @default.
• W2953618443 hasLocation W29536184432 @default.
• W2953618443 hasLocation W29536184433 @default.
• W2953618443 hasLocation W29536184434 @default.
• W2953618443 hasOpenAccess W2953618443 @default.
• W2953618443 hasPrimaryLocation W29536184431 @default.
• W2953618443 hasRelatedWork W1969593162 @default.
• W2953618443 hasRelatedWork W2027614408 @default.
• W2953618443 hasRelatedWork W2052622705 @default.
• W2953618443 hasRelatedWork W2109592716 @default.
• W2953618443 hasRelatedWork W2166116295 @default.
• W2953618443 hasRelatedWork W2953618443 @default.
• W2953618443 hasRelatedWork W2977686588 @default.
• W2953618443 hasRelatedWork W2979224157 @default.
• W2953618443 hasRelatedWork W3207246069 @default.
• W2953618443 hasRelatedWork W4212987560 @default.
• W2953618443 hasVolume "155" @default.
• W2953618443 isParatext "false" @default.
• W2953618443 isRetracted "false" @default.
• W2953618443 magId "2953618443" @default.
• W2953618443 workType "article" @default.